Quick Answer
DEXCOM INC reported Total Revenue of $4.66 billion for fiscal year 2025.
DEXCOM INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $4.66B +15.6% |
$4.03B +11.3% |
$3.62B +24.5% |
$2.91B +18.8% |
$2.45B +27.1% |
$1.93B +30.5% |
| Revenue (ASC 606) | $4.66B +15.6% |
$4.03B +11.3% |
$3.62B +24.5% |
$2.91B +18.8% |
$2.45B +27.1% |
$1.93B +30.5% |
| Net Income | $836.30M +45.1% |
$576.20M +6.4% |
$541.50M +58.7% |
$341.20M +57.3% |
$216.90M -60.5% |
$549.70M +443.7% |
| Diluted EPS | $2.09 +47.2% |
$1.42 +9.2% |
$1.30 +58.5% |
$0.82 +54.7% |
$0.53 -60.2% |
$1.33 +20.9% |
| Total Assets | $6.34B -2.2% |
$6.48B +3.5% |
$6.26B +16.2% |
$5.39B +9.3% |
$4.93B +15.0% |
$4.29B +79.1% |
| Cash and Equivalents | $917.70M +51.4% |
$606.10M +7.0% |
$566.30M -11.8% |
$642.30M -39.0% |
$1.05B +28.7% |
$817.60M +83.2% |
| Stockholders Equity | $2.75B +30.6% |
$2.10B +1.6% |
$2.07B -3.0% |
$2.13B +4.4% |
$2.04B +31.6% |
$1.55B +75.8% |
| R&D Expense | $599.10M +8.5% |
$552.40M +9.2% |
$505.80M +4.5% |
$484.20M -6.4% |
$517.10M +43.7% |
$359.90M +31.6% |
| Operating Income | $911.80M +52.0% |
$600.00M +0.4% |
$597.70M +52.8% |
$391.20M +47.2% |
$265.80M -11.3% |
$299.50M +110.5% |
| Gross Profit | $2.80B +14.9% |
$2.44B +6.5% |
$2.29B +21.5% |
$1.88B +12.1% |
$1.68B +31.3% |
$1.28B +37.4% |
| Shares Outstanding | 384.80M -1.5% |
390.70M +1.4% |
385.40M -0.2% |
386.30M -0.4% |
388.00M +303.7% |
96.10M +4.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.21B | +21.6% | +4.5% |
| Revenue (ASC 606) | September 30, 2025 | $1.21B | +21.6% | +4.5% |
| Net Income | September 30, 2025 | $283.80M | +110.8% | +57.8% |
| Diluted EPS | September 30, 2025 | $0.70 | +105.9% | +55.6% |
| Total Assets | September 30, 2025 | $7.50B | +18.0% | +2.4% |
| Cash and Equivalents | September 30, 2025 | $1.84B | +195.5% | +58.4% |
| Stockholders Equity | September 30, 2025 | $2.73B | +37.8% | +5.9% |
| R&D Expense | September 30, 2025 | $157.50M | +16.3% | +6.3% |
| Operating Income | September 30, 2025 | $242.50M | +59.5% | +14.1% |
| Gross Profit | September 30, 2025 | $731.40M | +23.2% | +6.2% |
| Shares Outstanding | September 30, 2025 | 390.00M | -0.2% | -0.6% |
- DEXCOM INC reported Total Revenue of $4.66 billion for fiscal year 2025.
- DEXCOM INC showed an increase of +15.6% in Total Revenue compared to the prior fiscal year.
- DEXCOM INC reported Revenue (ASC 606) of $4.66 billion for fiscal year 2025.
- DEXCOM INC showed an increase of +15.6% in Revenue (ASC 606) compared to the prior fiscal year.
- DEXCOM INC reported Net Income of $836.30 million for fiscal year 2025.
- DEXCOM INC showed an increase of +45.1% in Net Income compared to the prior fiscal year.
- DEXCOM INC reported Diluted EPS of $2.09 per share for fiscal year 2025.
- DEXCOM INC showed an increase of +47.2% in Diluted EPS compared to the prior fiscal year.
- DEXCOM INC reported Total Assets of $6.34 billion for fiscal year 2025.
- DEXCOM INC showed a decrease of -2.2% in Total Assets compared to the prior fiscal year.
- DEXCOM INC reported Cash and Equivalents of $917.70 million for fiscal year 2025.
- DEXCOM INC showed an increase of +51.4% in Cash and Equivalents compared to the prior fiscal year.
- DEXCOM INC reported Stockholders Equity of $2.75 billion for fiscal year 2025.
- DEXCOM INC showed an increase of +30.6% in Stockholders Equity compared to the prior fiscal year.
- DEXCOM INC reported R&D Expense of $599.10 million for fiscal year 2025.
- DEXCOM INC showed an increase of +8.5% in R&D Expense compared to the prior fiscal year.
- DEXCOM INC reported Operating Income of $911.80 million for fiscal year 2025.
- DEXCOM INC showed an increase of +52.0% in Operating Income compared to the prior fiscal year.
- DEXCOM INC reported Gross Profit of $2.80 billion for fiscal year 2025.
- DEXCOM INC showed an increase of +14.9% in Gross Profit compared to the prior fiscal year.
- DEXCOM INC reported Shares Outstanding of 384.80 million shares for fiscal year 2025.
- DEXCOM INC showed a decrease of -1.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: